Coulter Partners recently partnered with Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, and is pleased to announce the placement of J.D. Mowery as Chief Operating Officer (COO).
Reporting into the office of the CEO, Mowery will play an integral role in the continued evolution of Treadwell Therapeutics, leveraging his 20 years of industry experience and technical acumen.
“J.D. is widely considered an industry expert and thought leader on topics such as aseptic processing, cell & gene therapies, facility design, and contract manufacturing,” said Shane Burgess, co-CEO of Treadwell. “He is a key addition to Treadwell’s culture of purpose.”
“We are delighted to welcome J.D. into our organization. We are confident his operational experience in multiple modalities will bring significant value to Treadwell,” added Michael Tusche, Ph.D., co-CEO of Treadwell. “We are thankful to Coulter Partners for their extensive expertise and professionalism during this hire.”
Mowery has worked across multiple disciplines within the small molecule, mammalian, microbial, cell therapy and viral vector sectors, all while leading both drug product and drug substance organizations. He has also spent time on both the innovator and contract manufacturing side of the industry, gaining experience in contract negotiation, business development, and securing critical investments. During his time at Genentech, Lonza, Juno/Celgene, and most recently AGC Biologics, he has been continually recognized as an inspiring leader and mentor for his teams. Mowery earned a Bachelor of Science from George Fox University and a Master of Business Administration at Marylhurst University, both in Oregon.
“My career has taken me in many different directions, but I have always made those choices with a deep focus on learning and growing,” said Mowery. “The opportunity to join an organization that brings together all of my past experiences alongside such amazing vision, leadership, and devotion to the patient is a dream come true.”
About Treadwell Therapeutics
Treadwell Therapeutics is a science driven, clinical-stage multi-modality oncology company developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer. Treadwell’s robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945 and a best-in-class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1. Treadwell also has a strong pre-clinical pipeline with multiple biologic and next generation TCR based autologous cell therapy programs.
For more information about Treadwell Therapeutics, please visit www.treadwelltx.com.
Coulter Partners places first Chief Medical Officer at Enthera Pharmaceuticals
11 November 2021
Coulter Partners secures Chief Finance Officer and Non-Executive Director for Optimapharm
02 March 2021
Coulter Partners secures Chief Commercial Officer for Albumedix
02 June 2020
Vice President, Clinical Operations appointed for Incysus Therapeutics
14 May 2019